UroGen gets FDA review for new bladder cancer therapy

NDA FilingUGN-102Positive

AI Analysis

Summary

UroGen's new bladder cancer therapy has been accepted for FDA review, per a Seeking Alpha headline. No further details such as PDUFA date or drug specifics were provided in the article text.

Outcome Details

FDA accepted for review a new bladder cancer therapy from UroGen; the article text provided contains only a headline with no further details.

Importance:5/10

Sentiment:

0.30

FDA reviewNDA acceptancebladder canceroncologyurology

Related Companies

$URGN

Read the original article

Published by Seeking Alpha Healthcare on October 19, 2026 1:25 PM

Read Original